LENVIMA®(LENVATINIB) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE THYMIC CARCINOMA IN JAPAN
Published date:
03/23/2021
Excerpt:
Eisai Co., Ltd….and MSD K.K….announced today that LENVIMA® (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.